Van Cutsem E - Search Results

1

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.

van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, van Pelt J. van Malenstein H, et al. Among authors: van cutsem e, van pelt j. Cancer Lett. 2013 Feb 1;329(1):74-83. doi: 10.1016/j.canlet.2012.10.021. Epub 2012 Oct 27. Cancer Lett. 2013. PMID: 23111106

2

Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration.

Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verberckmoes R, De Groote J. Fevery J, et al. Among authors: van cutsem e, van steenbergen w. J Hepatol. 1990 Sep;11(2):153-8. doi: 10.1016/0168-8278(90)90106-2. J Hepatol. 1990. PMID: 2123913

3

The medical treatment of colorectal cancer: actual status and new developments.

Van Cutsem E, Peeters M, Verslype C, Filez L, Haustermans K, Janssens J. Van Cutsem E, et al. Hepatogastroenterology. 1999 Mar-Apr;46(26):709-16. Hepatogastroenterology. 1999. PMID: 10370599 Review.

4

The treatment of advanced colorectal cancer: where are we now and where do we go?

Van Cutsem E, Verslype C, Demedts I. Van Cutsem E, et al. Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):319-30. doi: 10.1053/bega.2002.0288. Best Pract Res Clin Gastroenterol. 2002. PMID: 11969241 Review.

5

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Van Cutsem E, et al. Among authors: van de velde h. J Clin Oncol. 2004 Apr 15;22(8):1430-8. doi: 10.1200/JCO.2004.10.112. J Clin Oncol. 2004. PMID: 15084616 Clinical Trial.

6

Systemic treatment of pancreatic cancer.

Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C. Van Cutsem E, et al. Among authors: van steenbergen w. Eur J Gastroenterol Hepatol. 2004 Mar;16(3):265-74. doi: 10.1097/00042737-200403000-00004. Eur J Gastroenterol Hepatol. 2004. PMID: 15195889 Review.

7

Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.

Van Cutsem E, Verslype C, Tejpar S. Van Cutsem E, et al. Semin Oncol. 2005 Feb;32(1):43-51. doi: 10.1053/j.seminoncol.2004.09.028. Semin Oncol. 2005. PMID: 15726505 Review.

8

Leptomeningeal carcinomatosis associated with oesophageal adenocarcinoma: two case reports and review of the literature.

Goddeeris K, Verslype C, Wilms G, Van Cutsem E. Goddeeris K, et al. Among authors: van cutsem e. Acta Gastroenterol Belg. 2006 Oct-Dec;69(4):377-80. Acta Gastroenterol Belg. 2006. PMID: 17343079

9

Lessons learned in the management of advanced pancreatic cancer.

Van Cutsem E, Verslype C, Grusenmeyer PA. Van Cutsem E, et al. J Clin Oncol. 2007 May 20;25(15):1949-52. doi: 10.1200/JCO.2006.09.4664. Epub 2007 Apr 23. J Clin Oncol. 2007. PMID: 17452675 No abstract available.

10

Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.

Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, Van Cutsem E. Tejpar S, et al. Among authors: van cutsem e. Lancet Oncol. 2007 May;8(5):387-94. doi: 10.1016/S1470-2045(07)70108-0. Lancet Oncol. 2007. PMID: 17466895

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

742 results

Search Page

Filters